PUNE, India, July 15, 2016 /PRNewswire/ --
ReportsnReports.com adds "Meningitis - Pipeline Review, H1 2016" to itsstore providing an overview of the Meningitis's therapeutic pipeline complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with
Complete report on H1 2016 pipeline review of Meningitis with 25 market data tables and 14 figures, spread across 63 pages is available at http://www.reportsnreports.com/reports/622314-meningitis-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Meningitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Meningitis Pipeline Review, H1 2016 report include Adenium Biotech ApS, Amplyx Pharmaceuticals, Inc., Chiesi Farmaceutici SpA, ContraFect Corporation, Genticel S.A., LG Life Science LTD., Matinas BioPharma Holdings, Inc., Sanofi Pasteur SA and Viamet Pharmaceuticals, Inc. Drug profiles mentioned in this research report includes amphotericin B, AP-114, CF-302, CF-303, CF-305, CF-309, Eupenta, LBVD, meningitis vaccine, meropenem, pneumococcal [serotype 4, 6A] vaccine, Small Molecules to Inhibit Pkh2-02 for Cryptococcal Meningitis, Streptococcus pneumonia vaccine, tuberculous meningitis vaccine, viral vaccine and VT-1129.
Order a copy of Meningitis - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=622314 .
Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening. Viral meningitis is not life-threatening and the people affected with this can be cured and recover quickly, but bacterial meningitis is serious and life-threatening. There are three major bacteria which lead to bacterial meningitis. Neisseria meningitides are one one of these, and causes meningococcal meningitis. Researchers have identified 13 major serogroups of N. meningitides, out of which the majority of cases are from one of five serogroups: A, B, C, Y and W-135. Drugs and vaccines are available to treat the serogroups AC, C, ACWY, and A. There are also vaccines available to prevent meningitis caused by serogroups A, C, Y, W-135. There are no vaccines or drugs available for the prevention and treatment of meningococcal meningitis caused by serogroup B. This represents a major unmet need in the market. Pneumococcal meningitis is another major bacterial cause of meningitis, caused by the bacteria streptococcus pneumonia, while haemophilius influenza is the third, and causes meningitis in infants. Approximatiely 44-46% cases of bacterial meningitis have all of the following three symptoms - severe headache, nuchal ridgidity ((inability to flex the neck forward passively due to increased neck muscle tone and stiffness) and altered mental status. Out of this triad of symptoms severe headache is the most common and occurs in 90% of the cases. If nove of the above mentioned symptoms are present, then occurrence of bacterial meningitis is least likely.Other clinical feature include photophobia (fear of bright light), phonophobia (fear of loud noises). In small children above symptoms are difficult to spot. Vague symptoms like irritability and unwell appearance are more common in them. In infants up to 6 months bulging of the fontanelle (soft spot on baby's head) may be visible. Other less severe illnesses like extreme cold, abnormality in skin color and leg pain may also be distinguishing features for meningitis. The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Another newly published market research report titled on Neurofibromatoses - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Neurofibromatoses, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses and special features on late-stage and discontinued projects. Companies discussed in this research are Alexion Pharmaceuticals, Inc., Arno Therapeutics, Inc., AstraZeneca Plc, CalAsia Pharmaceuticals, Inc., Kolltan Pharmaceuticals, Inc., Lixte Biotechnology Holdings, Inc., Novartis AG and Pfizer Inc. Neurofibromatoses Pipeline market research report of 73 pages is available at http://www.reportsnreports.com/reports/622308-neurofibromatoses-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. + 1 888 391 5441 email@example.com
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Subscribe to our Free Newsletters!